[Annual therapeutic advances in advanced non-small cell lung cancer in 2024]

This paper reviews the clinical progress achieved in 2024 in the field of advanced non-small cell lung cancer (NSCLC), both nationally and internationally. In the area of targeted therapy, particularly for rare mutations, new targets beyond EGFR, ALK, and ROS1 mutations, such as KRAS G12C, HER2, and MET, have gained more clinical validation and approval for targeted drugs in 2024. KRAS G12C inhibitors have also shown significant improvements in disease control rates for patients. Novel dual-target inhibitors are increasingly attracting increasing attention, as these drugs target both primary driver mutations and secondary mutations associated with resistance, thus overcoming the resistance problemsoften seen with traditional targeted therapies. This approach has demonstrated the potential to extend progression-free survival (PFS) in clinical settings. Immunotherapy with PD-1/PD-L1 inhibitors will remain an important treatment option for advanced lung cancer in 2024. While single-agent immunotherapy has limited efficacy in some patients, new combination therapies have shown promising potential, particularly the combination of immune checkpoint inhibitors with chemotherapy, anti-angiogenesis drugs, and targeted therapies, which has been shown to significantly improve efficacy. Antibody-drug conjugates (ADCs) targeting HER2 mutations have also been approved. The development of anti-cancer drugs continues to evolve, with new combinations and strategies being actively explored.